PCM
ALT icon

Penserra Capital Management’s Altimmune ALT Stock Holding History

Penserra Capital Management’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,587
Closed -$7K – 1024
2025
Q1 		$7K Buy
1,587
+239
+18% +$1.51K ﹤0.01% 903
2024
Q4 		$9K Buy
1,348
+74
+6% +$565 ﹤0.01% 1034
2024
Q3 		$7K Buy
1,274
+392
+44% +$2.66K ﹤0.01% 907
2024
Q2 		$6K Buy
+882
New +$6.51K ﹤0.01% 1043
2021
Q4 		– Sell
-910
Closed -$10K – 1359
2021
Q3 		$10K Buy
910
+35
+4% +$426 ﹤0.01% 1353
2021
Q2 		$8K Buy
875
+30
+4% +$410 ﹤0.01% 1284
2021
Q1 		$11K Buy
845
+85
+11% +$1.37K ﹤0.01% 1020
2020
Q4 		$8K Buy
+760
New +$8.96K ﹤0.01% 947

Other funds holding ALT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Penserra Capital Management's ALT Position: Q2 2025 in Review

Penserra Capital Management sold out of Altimmune (ALT) in Q2 2025, closing a stake of 1,587 shares — an estimated $7K sold.

Penserra Capital Management first reported a position in ALT in Q4 2020 and held it in 8 quarters. The position peaked at $11K in Q1 2021. 180 funds tracked by Wall St. Rank hold ALT as of Q2 2025.

  • Penserra Capital Management reported no remaining Altimmune position as of Q2 2025 after selling out during the quarter.
  • Penserra Capital Management sold 1,587 Altimmune shares in Q2 2025, an estimated $7K.
  • Penserra Capital Management first reported a position in Altimmune in Q4 2020 and held it in 8 quarters.
  • Penserra Capital Management's Altimmune position peaked at $11K in Q1 2021.
  • 180 funds tracked by Wall St. Rank held Altimmune as of Q2 2025.

Based on Penserra Capital Management's 13F filing for Q2 2025, filed 6 Aug 2025.